HIV meds may have a new target: a vulnerable spot on the doughnut-shaped protease enzyme. This HIV enzyme reassembles proteins, enabling the virus to reproduce. Protease inhibitor meds (PIs) disrupt one point on the enzyme, but new research focuses on a different area. The potential hole in the news? The new target is only speculative, based on computer modeling. But if it pans out, people with resistance to today's PIs may get a new option. Wouldn't that be delish?!